Navigation Links
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster
Date:7/20/2009

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development.

The collaboration will begin with a selection of ten small molecule candidates, discovered by LLS grant-funded academic researchers, deemed to have the most promise of advancing into clinical trials in the shortest period of time. FORMA will use its proprietary Computational Solvent (CS) Mapping technology to aid in structure based drug design with expert computer modeling, screening and medicinal chemistry competence to optimize and prioritize molecules that LLS and its partners may take to the clinic.

The partnership between LLS and FORMA is the latest in LLS's Therapy Acceleration Program (TAP), a bold initiative intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. Through TAP, LLS is taking a results-oriented approach, partnering directly with biotechnology companies to move promising therapies more quickly along the FDA drug approval critical path.

"With its sophisticated technology suite and internal expertise to expeditiously progress the development of novel therapies, FORMA is an ideal partner to help LLS identify and optimize the most promising drug candidates and to achieve our mission of advancing life-saving blood cancer therapeutics," said John Walter LLS's chief executive officer.

"LLS has assembled a promising portfolio of innovative programs to combat a wide range of hematological cancers," says FORMA CEO Steve Tregay, Ph.D. "The team at FORMA is excited to be working with LLS on this bold initiative by providing our unique suite of drug discovery technologies to quickly translate science from the laboratory to patients in clinical trials."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About FORMA Therapeutics

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. Capitalizing on the targets and pathways validated by the Cancer Genome Atlas Project and other related efforts, FORMA is developing a new generation of cancer therapies aimed at previously elusive drug targets. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing. www.formatherapeutics.com.

    Contact: LLS: Andrea Greif
            (914) 821-8958  andrea.greif@lls.org

    FORMA:   Steven Tregay, CEO
             (617) 679-1970

    FORMA Media Contact:
    MacDougall Biomedical Communications
    Douglas MacDougall or Jennifer Conrad
    (781) 235-3060


'/>"/>
SOURCE The Leukemia & Lymphoma Society (LLS)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leukemia/Lymphoma Society Pleased to Announce Partnership in Southern Ohio with Eisen Marketing Group
2. 2009 recipient of minority scholar award begins clinical research on leukemia
3. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
4. New Drug Could Work Against Leukemia
5. Leukemia & Lymphoma Society Recognizes Aurora Physician as Man of the Year
6. For Kids With Leukemia, Radiation May Be Safe to Skip
7. The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense
8. Taking Aim at Relapse of Leukemia in Kids
9. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
10. Study IDs benefit of donor SCT for adults with acute myeloid leukemia
11. Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 26, 2017 , ... Global healthcare company Novo Nordisk, renewed ... company’s commitment to the world’s first all-diabetes professional cycling team to a total ... partnered with the professional cycling team Team Type 1 to create Team Novo ...
(Date:9/26/2017)... ... September 26, 2017 , ... After a summer-long contest ... Campaign for Designated Drivers proudly announced the winners of the HEROtini Mocktail Challenge ... restaurants took on the challenge of competing in three categories: Best HEROtini Mocktail, ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... expands services in Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, ... Analysis (ABA) services. Aspire provides center based Autism services in Broomfield and will ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort ... “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation of published ... Hays Sate University, who has worked at a local mental health center for over ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: